1
|
Modroiu A, Marzullo L, Orlandini S, Gotti R, Hancu G, Furlanetto S. Analytical quality by design-based development of a capillary electrophoresis method for Omeprazole impurity profiling. J Pharm Biomed Anal 2024; 248:116295. [PMID: 38879949 DOI: 10.1016/j.jpba.2024.116295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2024] [Revised: 06/05/2024] [Accepted: 06/06/2024] [Indexed: 06/18/2024]
Abstract
Omeprazole (OME) is a proton pump inhibitor used to treat gastroesophageal reflux disease associated conditions. The current study presents an Analytical Quality by Design-based approach for the development of a CE method for OME impurity profiling. The scouting experiments suggested the selection of solvent modified Micellar ElectroKinetic Chromatography operative mode using a pseudostationary phase composed of sodium dodecyl sulfate (SDS) micelles and n-butanol as organic modifier in borate buffer. A symmetric three-level screening matrix 37//16 was used to evaluate the effect of Critical Method Parameters, including Background Electrolyte composition and instrumental settings, on Critical Method Attributes (critical resolution values, OME peak width and analysis time). The analytical procedure was optimized using Response Surface Methodology through a Central Composite Orthogonal Design. Risk of failure maps made it possible to define the Method Operable Design Region, within which the following optimized conditions were selected: 72 mM borate buffer pH 10.0, 96 mM SDS, 1.45 %v/v n-butanol, capillary temperature 21 °C, applied voltage 25 kV. The method was validated according to ICH guidelines and robustness was evaluated using a Plackett-Burman design. The developed procedure enables the simultaneous determination of OME and seven related impurities, and has been successfully applied to the analysis of pharmaceutical formulations.
Collapse
Affiliation(s)
- Adriana Modroiu
- Department of Pharmaceutical and Therapeutic Chemistry, Faculty of Pharmacy, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology of Târgu Mureş, Gh. Marinescu 38, Târgu Mureş 540142, Romania; Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Sesto Fiorentino, Florence 50019, Italy
| | - Luca Marzullo
- Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Sesto Fiorentino, Florence 50019, Italy
| | - Serena Orlandini
- Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Sesto Fiorentino, Florence 50019, Italy.
| | - Roberto Gotti
- Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, Bologna 40126, Italy
| | - Gabriel Hancu
- Department of Pharmaceutical and Therapeutic Chemistry, Faculty of Pharmacy, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology of Târgu Mureş, Gh. Marinescu 38, Târgu Mureş 540142, Romania
| | - Sandra Furlanetto
- Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Sesto Fiorentino, Florence 50019, Italy
| |
Collapse
|
2
|
Brunelli C, Osborne R, Yule G, Dixon T, Bruce I, Taylor M. Automated multifactorial design of experiment and Bayesian optimisation algorithm approaches to method development for the green analysis by supercritical fluid chromatography of a pharmaceutical ingredient. J Chromatogr A 2024; 1732:465214. [PMID: 39116684 DOI: 10.1016/j.chroma.2024.465214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Revised: 07/22/2024] [Accepted: 07/24/2024] [Indexed: 08/10/2024]
Abstract
During drug development, chromatography is frequently used for purity and stability testing of both drug substance and drug product. Reversed phase liquid chromatography (RPLC) is one of the most widely used methodologies due to its wide scope of application. In the later stages of drug development, the specified impurities and degradation products that define the critical quality attribute of the final API, also known as Key Predictive Sample Set (KPSS), are usually well defined and controlled. At this point, a method review enables selecting the most appropriate technique which should be the one providing optimal robustness (ICH-Q14[1]), with the support of Quality by Design (QbD) approaches. Supercritical Fluid Chromatography (SFC) is a preferred technique for its proven diversity in selectivity. The adoption of a technique which presents the most favourable environmental impact, such as, but not limited to, SFC, is also becoming increasingly important as laboratories strive to reduce carbon footprint. Re-developing a method requires high resource-demands in terms of staff, materials, and time. Any step of the process that can be automated can facilitate this approach, speeding up the delivery of the method whilst preserving robustness. In this article we describe how an SFC method was developed for the purity profiling of a late-stage oncology candidate, taking advantage of the superior selectivity of SFC towards structurally similar analytes, owed to the high orthogonality with R2 as low as 0.014 towards the KPSS. We describe two approaches to automate the method development. Firstly, a multifactorial design of experiments (DoE) and secondly, an optimization via a Bayesian algorithm, which was completed in one night, highlighting the potential and limitations, with an insight into the robustness. Both methods achieved baseline separation with varying levels of automation embedded into the process and a large reduction of the resource demands when compared to traditional optimisation methods. Finally, we describe the beneficial environmental impact that implementing SFC methods can yield, with a calculated green score reduced to a value between 17 and 30 % compared to RPLC, depending on the number of runs per sequence.
Collapse
Affiliation(s)
- Claudio Brunelli
- Pfizer UK R&D Ltd, Analytical R&D, Ramsgate Road, Sandwich -Kent CT13 9ND, United Kingdom.
| | - Ryan Osborne
- Pfizer UK R&D Ltd, Analytical R&D, Ramsgate Road, Sandwich -Kent CT13 9ND, United Kingdom
| | - Greg Yule
- Pfizer UK R&D Ltd, Analytical R&D, Ramsgate Road, Sandwich -Kent CT13 9ND, United Kingdom
| | - Tom Dixon
- University of Leeds, Institute of process research and development (iPRD). Woodhouse, Leeds LS2 9JT, United Kingdom
| | - Isobel Bruce
- Pfizer UK R&D Ltd, Analytical R&D, Ramsgate Road, Sandwich -Kent CT13 9ND, United Kingdom
| | - Mark Taylor
- Pfizer UK R&D Ltd, Analytical R&D, Ramsgate Road, Sandwich -Kent CT13 9ND, United Kingdom
| |
Collapse
|
3
|
Nompari L, Coccone SS, Sardone GL, Corrado A, Berti S, Biagini M, Rovini M, Magagnoli C, Cianetti S, Orlandini S, Furlanetto S, De Ricco R. Innovative Reversed-Phase Chromatography Platform Approach for the Fast and Accurate Characterization of Membrane Vesicles' Protein Patterns. ACS Pharmacol Transl Sci 2024; 7:1584-1594. [PMID: 38751636 PMCID: PMC11091982 DOI: 10.1021/acsptsci.4c00112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Revised: 03/27/2024] [Accepted: 04/01/2024] [Indexed: 05/18/2024]
Abstract
Outer membrane vesicles (OMVs) have been widely explored to develop vaccine candidates for bacterial pathogens due to their ability to combine adjuvant properties with immunogenic activity. OMV expresses a variety of proteins and carbohydrate antigens on their surfaces. For this reason, there is an analytical need to thoroughly characterize the species expressed at their surface: we here present a simple and accurate reversed-phase ultrahigh-performance liquid chromatography (RP-UPLC) method developed according to quality by design principles. This work provides an analytical alternative to the classical sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) characterization. The higher selectivity and sensitivity of the RP-UHPLC assay allow for the identification of additional protein species with respect to SDS-PAGE and facilitate its precise relative abundance quantification. According to validation results, the assay showed high accuracy, linearity, precision, repeatability, and a limit of quantification of 1% for less abundant proteins. This performance paves the way for improved production campaign consistency while also being analytically simple (no sample pretreatment required), making it suitable for routine quality control testing. In addition, the applicability of the assay to a wider range of vesicle classes (GMMA) was demonstrated.
Collapse
Affiliation(s)
- Luca Nompari
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | | | - Gian Luca Sardone
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Alessio Corrado
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Stefania Berti
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Massimiliano Biagini
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Michele Rovini
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Claudia Magagnoli
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Simona Cianetti
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Serena Orlandini
- Department
of Chemistry “U. Schiff″, University of Florence, Via U. Schiff 6, Sesto Fiorentino 50019, Florence, Italy
| | - Sandra Furlanetto
- Department
of Chemistry “U. Schiff″, University of Florence, Via U. Schiff 6, Sesto Fiorentino 50019, Florence, Italy
| | - Riccardo De Ricco
- GSK,
Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| |
Collapse
|
4
|
Nompari L, Orlandini S, Pasquini B, Fontana L, Rovini M, Masi F, Gotti R, Furlanetto S. Optimization of hydrolysis conditions of amino acid analysis for UHPLC-UV antigens content determination: Bexsero vaccine a case study. J Pharm Biomed Anal 2024; 241:115997. [PMID: 38325191 DOI: 10.1016/j.jpba.2024.115997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 01/12/2024] [Accepted: 01/19/2024] [Indexed: 02/09/2024]
Abstract
In the present study the compositional analysis of the amino acids released by the acidic hydrolysis of the vaccine antigens was approached as an alternative to the dye-binding methods, for improvement of the quality control. In particular, the Analytical Quality by Design principles were undertaken in optimizing the hydrolysis conditions of the antigens to be applied prior to the quantitation by UHPLC-UV. Bexsero was used as a case study; it is a recombinant meningococcal B vaccine and one of its critical quality attributes is the content of the three core protein antigens, namely Neisseria Heparin Binding Antigen, factor H binding protein and Neisseria adhesin A, in the final formulation. Conventionally, the proteins quantitation is carried out by dye-binding assays. Analytical Target Profile was defined as the accurate determination of amounts of the Bexsero antigens. The Critical Method Parameters were chosen by means of the cause-effect matrix. A Face Centered Design was used to select the experiments to investigate the process and finally a Method Operable Design Region with a risk of failure of 5% was defined. The selected working point for routine use was: hydrolysis time, 17 hrs; temperature, 112 °C; 6 M HCl volume, 300 µl; antioxidant 90% phenol volume, 5 µl.
Collapse
Affiliation(s)
- Luca Nompari
- GSK, Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy.
| | - Serena Orlandini
- Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Benedetta Pasquini
- Ethics Committee Secretariat Officer Area Vasta Centro, AOU Careggi, Largo Brambilla 3, 50134 Florence, Italy
| | - Letizia Fontana
- GSK, Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Michele Rovini
- GSK, Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Flavio Masi
- GSK, Technical Research and Development (TRD), Via Fiorentina 1, 53100 Siena, Italy
| | - Roberto Gotti
- Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | - Sandra Furlanetto
- Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Italy.
| |
Collapse
|
5
|
Borman PJ, Guiraldelli AM, Weitzel J, Thompson S, Ermer J, Roussel JM, Marach J, Sproule S, Pappa HN. Ongoing Analytical Procedure Performance Verification Using a Risk-Based Approach to Determine Performance Monitoring Requirements. Anal Chem 2024; 96:966-979. [PMID: 38191128 PMCID: PMC10809227 DOI: 10.1021/acs.analchem.3c03708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 11/21/2023] [Accepted: 11/21/2023] [Indexed: 01/10/2024]
Abstract
The analytical procedure life cycle (APLC) provides a holistic framework to ensure analytical procedure fitness for purpose. USP's general chapter <1220> considers the validation activities that take place across the entire analytical procedure lifecycle and provides a three-stage framework for its implementation. Performing ongoing analytical procedure performance verification (OPPV) (stage 3) ensures that the procedure remains in a state of control across its lifecycle of use post validation (qualification) and involves an ongoing program to collect and analyze data that relate to the performance of the procedure. Knowledge generated during stages 1 (procedure design) and 2 (procedure performance qualification) is used as the basis for the design of the routine monitoring plan to support performance verification (stage 3). The extent of the routine monitoring required should be defined based on risk assessment, considering the complexity of the procedure, its intended purpose, and knowledge about process/procedure variability. The analytical target profile (ATP) can be used to provide or guide the establishment of acceptance criteria used to verify the procedure performance during routine use (e.g., through a system/sample suitability test (SST) or verification criteria applicable to procedure changes or transfers). An ATP however is not essentially required to perform OPPV, and a procedure performance monitoring program can be implemented even if the full APLC framework has not been applied. In these situations, verification criteria can be derived from existing validation or system suitability criteria. Elements of the life cycle approach can also be applied retrospectively if deemed useful.
Collapse
Affiliation(s)
- Phil J. Borman
- US
Pharmacopeia 12601 Twinbrook Pkwy, Rockville, Maryland 20851, United States
| | | | - Jane Weitzel
- US
Pharmacopeia 12601 Twinbrook Pkwy, Rockville, Maryland 20851, United States
| | - Sarah Thompson
- AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, United Kingdom
| | - Joachim Ermer
- US
Pharmacopeia 12601 Twinbrook Pkwy, Rockville, Maryland 20851, United States
| | - Jean-Marc Roussel
- US
Pharmacopeia 12601 Twinbrook Pkwy, Rockville, Maryland 20851, United States
| | - Jaime Marach
- US
Pharmacopeia 12601 Twinbrook Pkwy, Rockville, Maryland 20851, United States
| | - Stephanie Sproule
- US
Pharmacopeia 12601 Twinbrook Pkwy, Rockville, Maryland 20851, United States
| | - Horacio N. Pappa
- US
Pharmacopeia 12601 Twinbrook Pkwy, Rockville, Maryland 20851, United States
| |
Collapse
|
6
|
Simeoni P, Deissler M, Bienert R, Gritsch M, Nerkamp J, Kirsch S, Roesli C, Pohl T, Anderka O, Gellermann G. Using enhanced development tools offered by analytical Quality by Design to support switching of a quality control method. Biotechnol Bioeng 2023; 120:3299-3310. [PMID: 37526307 DOI: 10.1002/bit.28517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 07/10/2023] [Accepted: 07/11/2023] [Indexed: 08/02/2023]
Abstract
Quality by Design (QbD) principles play an increasingly important role in the pharmaceutical industry. Here, we used an analytical QbD (AQbD) approach to develop a capillary electrophoresis sodium dodecyl sulfate under reducing conditions (rCE-SDS), with the aim of replacing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) as release and stability test method for a commercialized monoclonal antibody product. Method development started with defining analytical method performance requirements as part of an analytical target profile, followed by a systematic risk assessment of method input parameters and their relation to defined method outputs. Based on this, design of experiments studies were performed to identify a method operable design region (MODR). The MODR could be leveraged to improve method robustness. In a bridging study, it was demonstrated that the rCE-SDS method is more sensitive than the legacy SDS-PAGE method, and a conversion factor could be established to compensate for an off-set due to the higher sensitivity, without losing the correlation to the historical data acquired with the former method. Overall, systematic application of analytical Quality by Design principles for designing and developing a new analytical method helped to elucidate the complex dependency of method outputs on its input parameters. The link of the method to product quality attributes and the definition of method performance requirements were found to be most relevant for derisking the analytical method switch, regarding impact on the control strategy.
Collapse
Affiliation(s)
| | | | - Roland Bienert
- Technical R&D Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Manuela Gritsch
- Technical R&D Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Jörg Nerkamp
- Technical R&D Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Stephan Kirsch
- Technical R&D Biologics, Novartis Pharma AG, Basel, Switzerland
| | | | - Thomas Pohl
- Technical R&D Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Oliver Anderka
- Technical R&D Biologics, Novartis Pharma AG, Basel, Switzerland
| | | |
Collapse
|
7
|
Jiang Z, Dalby PA. Challenges in scaling up AAV-based gene therapy manufacturing. Trends Biotechnol 2023; 41:1268-1281. [PMID: 37127491 DOI: 10.1016/j.tibtech.2023.04.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 04/05/2023] [Accepted: 04/06/2023] [Indexed: 05/03/2023]
Abstract
Accelerating the scale up of adeno-associated virus (AAV) manufacture is highly desirable to meet the increased demand for gene therapies. However, the development of bioprocesses for AAV gene therapies remains time-consuming and challenging. The quality by design (QbD) approach ensures bioprocess designs that meet the desired product quality and safety profile. Rapid stress tests, developability screens, and scale-down technologies have the potential to streamline AAV product and manufacturing bioprocess development within the QbD framework. Here we review how their successful use for antibody manufacture development is translating to AAV, but also how this will depend critically on improved analytical methods and adaptation of the tools as more understanding is gained on the critical attributes of AAV required for successful therapy.
Collapse
Affiliation(s)
- Ziyu Jiang
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK.
| | - Paul A Dalby
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK.
| |
Collapse
|
8
|
Li X. Recent applications of quantitative mass spectrometry in biopharmaceutical process development and manufacturing. J Pharm Biomed Anal 2023; 234:115581. [PMID: 37494866 DOI: 10.1016/j.jpba.2023.115581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 06/27/2023] [Accepted: 07/12/2023] [Indexed: 07/28/2023]
Abstract
Biopharmaceutical products have seen rapid growth over the past few decades and continue to dominate the global pharmaceutical market. Aligning with the quality by design (QbD) framework and realization, recent advances in liquid chromatography-mass spectrometry (LC-MS) instrumentation and related techniques have enhanced biopharmaceutical characterization capabilities and have supported an increased development of biopharmaceutical products. Beyond its routine qualitative characterization, the quantitative feature of LC-MS has unique applications in biopharmaceutical process development and manufacturing. This review describes the recent applications and implications of the advancement of quantitative MS methods in biopharmaceutical process development, and characterization of biopharmaceutical product, product-related variants, and process-related impurities. We also provide insights on the emerging applications of quantitative MS in the lifecycle of biopharmaceutical product development including quality control in the Good Manufacturing Practice (GMP) environment and process analytical technology (PAT) practices during process development and manufacturing. Through collaboration with instrument and software vendors and regulatory agencies, we envision broader adoption of phase-appropriate quantitative MS-based methods for the analysis of biopharmaceutical products, which in turn has the potential to enable manufacture of higher quality products for patients.
Collapse
Affiliation(s)
- Xuanwen Li
- Analytical Research and Development, MRL, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, NJ 07065, USA.
| |
Collapse
|
9
|
Chiarentin L, Gonçalves C, Augusto C, Miranda M, Cardoso C, Vitorino C. Drilling into "Quality by Design" Approach for Analytical Methods. Crit Rev Anal Chem 2023:1-42. [PMID: 37665603 DOI: 10.1080/10408347.2023.2253321] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
The need for consistency in analytical method development reinforces the dependence of pharmaceutical product development and manufacturing on robust analytical data. The Analytical Quality by Design (AQbD), akin to the product Quality by Design (QbD) endows a high degree of confidence to the method quality developed. AQbD involves the definition of the analytical target profile as starting point, followed by the identification of critical method variables and critical analytical attributes, supported on risk assessment and design of experiment tools for the establishment of a method operable design region and control strategy of the method. This systematic approach moves away from reactive troubleshooting to proactive failure reduction. The objective of this review is to highlight the elements of the AQbD framework and provide an overview of their implementation status in various analytical methods used in the pharmaceutical field. These methodologies include but are not limited to, high-performance liquid chromatography, UV-Vis spectrophotometry, capillary electrophoresis, supercritical fluid chromatography, and high-performance thin-layer chromatography. Finally, a critical appraisal is provided to highlight how regulators have encouraged AQbD principles application to boost the prevention of method failures and a better understanding of the method operable design region (MODR) and control strategy, ultimately resulting in cost-effectiveness and regulatory flexibility.
Collapse
Affiliation(s)
- Lucas Chiarentin
- Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
- Laboratórios Basi Indústria Farmacêutica S.A, Parque Industrial Manuel Lourenço Ferreira, Mortágua, Portugal
- Coimbra Chemistry Centre, Institute of Molecular Sciences - IMS, Department of Chemistry, University of Coimbra, Coimbra, Portugal
| | - Carla Gonçalves
- Laboratórios Basi Indústria Farmacêutica S.A, Parque Industrial Manuel Lourenço Ferreira, Mortágua, Portugal
| | - Cátia Augusto
- Laboratórios Basi Indústria Farmacêutica S.A, Parque Industrial Manuel Lourenço Ferreira, Mortágua, Portugal
| | - Margarida Miranda
- Laboratórios Basi Indústria Farmacêutica S.A, Parque Industrial Manuel Lourenço Ferreira, Mortágua, Portugal
- Egas Moniz School of Health and Science, Egas Moniz Center of Interdisciplinary Research (CiiEM), Caparica, Portugal
| | - Catarina Cardoso
- Laboratórios Basi Indústria Farmacêutica S.A, Parque Industrial Manuel Lourenço Ferreira, Mortágua, Portugal
| | - Carla Vitorino
- Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
- Coimbra Chemistry Centre, Institute of Molecular Sciences - IMS, Department of Chemistry, University of Coimbra, Coimbra, Portugal
| |
Collapse
|
10
|
Castellanos MM, Gressard H, Li X, Magagnoli C, Moriconi A, Stranges D, Strodiot L, Tello Soto M, Zwierzyna M, Campa C. CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness. Vaccines (Basel) 2023; 11:1153. [PMID: 37514969 PMCID: PMC10386492 DOI: 10.3390/vaccines11071153] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 06/15/2023] [Accepted: 06/22/2023] [Indexed: 07/30/2023] Open
Abstract
This review reports on an overview of key enablers of acceleration/pandemic and preparedness, covering CMC strategies as well as technical innovations in vaccine development. Considerations are shared on implementation hurdles and opportunities to drive sustained acceleration for vaccine development and considers learnings from the COVID pandemic and direct experience in addressing unmet medical needs. These reflections focus on (i) the importance of a cross-disciplinary framework of technical expectations ranging from target antigen identification to launch and life-cycle management; (ii) the use of prior platform knowledge across similar or products/vaccine types; (iii) the implementation of innovation and digital tools for fast development and innovative control strategies.
Collapse
Affiliation(s)
- Maria Monica Castellanos
- Drug Product Development, Vaccines Technical R&D, GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA
| | - Hervé Gressard
- Project & Digital Sciences, Vaccines Technical R&D, GSK, Rue de l'Institut 89, 1330 Rixensart, Belgium
| | - Xiangming Li
- Drug Substance Development, Vaccines Technical R&D, GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA
| | - Claudia Magagnoli
- Analytical Research & Development, Vaccines Technical R&D, GSK, Via Fiorentina 1, 53100 Siena, Italy
| | - Alessio Moriconi
- Drug Product Development, Vaccines Technical R&D, GSK, Via Fiorentina 1, 53100 Siena, Italy
| | - Daniela Stranges
- Drug Product Development, Vaccines Technical R&D, GSK, Via Fiorentina 1, 53100 Siena, Italy
| | - Laurent Strodiot
- Drug Product Development, Vaccines Technical R&D, GSK, Rue de l'Institut 89, 1330 Rixensart, Belgium
| | - Monica Tello Soto
- Drug Substance Development, Vaccines Technical R&D, GSK, Rue de l'Institut 89, 1330 Rixensart, Belgium
| | - Magdalena Zwierzyna
- Project & Digital Sciences, Vaccines Technical R&D, GSK, Via Fiorentina 1, 53100 Siena, Italy
| | - Cristiana Campa
- Vaccines Global Technical R&D, GSK, Via Fiorentina 1, 53100 Siena, Italy
| |
Collapse
|
11
|
Marzullo L, Gotti R, Orlandini S, Slavíčková P, Jireš J, Zapadlo M, Douša M, Nekvapilová P, Řezanka P, Furlanetto S. Analytical Quality by Design-Compliant Development of a Cyclodextrin-Modified Micellar ElectroKinetic Chromatography Method for the Determination of Trimecaine and Its Impurities. Molecules 2023; 28:4747. [PMID: 37375300 DOI: 10.3390/molecules28124747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 06/01/2023] [Accepted: 06/11/2023] [Indexed: 06/29/2023] Open
Abstract
In 2022, the International Council for Harmonisation released draft guidelines Q2(R2) and Q14, intending to specify the development and validation activities that should be carried out during the lifespan of an analytical technique addressed to assess the quality of medicinal products. In the present study, these recommendations were implemented in Capillary Electrophoresis method development for the quality control of a drug product containing trimecaine, by applying Analytical Quality by Design. According to the Analytical Target Profile, the procedure should be able to simultaneously quantify trimecaine and its four impurities, with specified analytical performances. The selected operative mode was Micellar ElectroKinetic Chromatography employing sodium dodecyl sulfate micelles supplemented with dimethyl-β-cyclodextrin, in a phosphate-borate buffer. The Knowledge Space was investigated through a screening matrix encompassing the composition of the background electrolyte and the instrumental settings. The Critical Method Attributes were identified as analysis time, efficiency, and critical resolution values. Response Surface Methodology and Monte Carlo Simulations allowed the definition of the Method Operable Design Region: 21-26 mM phosphate-borate buffer pH 9.50-9.77; 65.0 mM sodium dodecyl sulfate; 0.25-1.29% v/v n-butanol; 21-26 mM dimethyl-β-cyclodextrin; temperature, 22 °C; voltage, 23-29 kV. The method was validated and applied to ampoules drug products.
Collapse
Affiliation(s)
- Luca Marzullo
- Department of Chemistry "U. Schiff", University of Florence, 50019 Sesto Fiorentino, Italy
| | - Roberto Gotti
- Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy
| | - Serena Orlandini
- Department of Chemistry "U. Schiff", University of Florence, 50019 Sesto Fiorentino, Italy
| | | | - Jakub Jireš
- Zentiva, k.s., 10237 Prague, Czech Republic
- Department of Analytical Chemistry, Faculty of Chemical Engineering, UCT Prague, 16628 Prague, Czech Republic
| | | | | | - Pavla Nekvapilová
- Department of Analytical Chemistry, Faculty of Chemical Engineering, UCT Prague, 16628 Prague, Czech Republic
| | - Pavel Řezanka
- Department of Analytical Chemistry, Faculty of Chemical Engineering, UCT Prague, 16628 Prague, Czech Republic
| | - Sandra Furlanetto
- Department of Chemistry "U. Schiff", University of Florence, 50019 Sesto Fiorentino, Italy
| |
Collapse
|
12
|
Ntontis S, Tsanaktsidou E, Tzanavaras PD, Kachrimanis K, Markopoulou CK, Zacharis CK. Analytical quality by design approach for the determination of imidazole in sildenafil API and its formulations using zwitterionic HILIC stationary phase. J Pharm Biomed Anal 2023; 224:115186. [PMID: 36455394 DOI: 10.1016/j.jpba.2022.115186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Revised: 11/21/2022] [Accepted: 11/24/2022] [Indexed: 11/28/2022]
Abstract
Herein, the development of a HILIC method for the determination of imidazole (Imp E) in sildenafil citrate API and its final formulations is reported. The main goal of this study was to develop a robust, application-specific HPLC method according to the Analytical Quality by Design principles for the analysis of the above impurity. After the risk assessment study, the high-risk method parameters were sequentially screened and optimized by using 2-level fractional factorial and Box-Behnken designs. The mathematical models were combined with the Monte-Carlo simulations to identify the Method Operable Design Region. The method was thoroughly validated between 25 % and 150 % of the target concentration limit of the imidazole using the total-error concept. The relative bias varied between 1.6 % and 5.6 % and the RSD values were lower than 5.8 % for repeatability and intermediate precision. The limit of detection and the lower limit of quantification were satisfactory and found to be 0.025 and 0.125 μg mL-1 imidazole, respectively. The applicability of the proposed approach has been demonstrated in the analysis of several sildenafil citrate API batches and final products.
Collapse
Affiliation(s)
- Stefanos Ntontis
- Laboratory of Pharmaceutical Analysis, Department of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, GR-54124, Greece
| | - Eleni Tsanaktsidou
- Laboratory of Pharmaceutical Analysis, Department of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, GR-54124, Greece
| | - Paraskevas D Tzanavaras
- Laboratory of Analytical Chemistry, School of Chemistry, Faculty of Sciences, Aristotle University of Thessaloniki, GR-54124, Greece
| | - Kyriakos Kachrimanis
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece
| | - Catherine K Markopoulou
- Laboratory of Pharmaceutical Analysis, Department of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, GR-54124, Greece
| | - Constantinos K Zacharis
- Laboratory of Pharmaceutical Analysis, Department of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, GR-54124, Greece.
| |
Collapse
|
13
|
Han L, An C, Liu D, Wang Z, Bian L, He Q, Liu J, Wang Q, Liu M, Mao Q, Hang T, Wang A, Gao F, Tan D, Liang Z. Development of an ELISA Assay for the Determination of SARS-CoV-2 Protein Subunit Vaccine Antigen Content. Viruses 2022; 15:62. [PMID: 36680102 PMCID: PMC9860593 DOI: 10.3390/v15010062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 12/17/2022] [Accepted: 12/22/2022] [Indexed: 12/29/2022] Open
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein subunit vaccine is one of the mainstream technology platforms for the development of COVID-19 vaccines, and most R&D units use the receptor-binding domain (RBD) or spike (S) protein as the main target antigen. The complexity of vaccine design, sequence, and expression systems makes it urgent to establish common antigen assays to facilitate vaccine development. In this study, we report the development of a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to determine the antigen content of SARS-CoV-2 protein subunit vaccines based on the United States Pharmacopeia <1220> and ICH (international conference on harmonization) Q14 and Q2 (R2) requirements. A monoclonal antibody (mAb), 20D8, was identified as the detection antibody based on its high RBD binding activity (EC50 = 8.4 ng/mL), broad-spectrum anti-variant neutralizing activity (EC50: 2.7−9.8 ng/mL for pseudovirus and EC50: 9.6−127 ng/mL for authentic virus), good in vivo protection, and a recognized linear RBD epitope (369−379 aa). A porcine anti-RBD polyclonal antibody was selected as the coating antibody. Assay performance met the requirements of the analytical target profile with an accuracy and precision of ≥90% and adequate specificity. Within the specification range of 70−143%, the method capability index was >0.96; the misjudgment probability was <0.39%. The method successfully detected SARS-CoV-2 protein subunit vaccine antigens (RBD or S protein sequences in Alpha, Beta, Gamma, or Delta variants) obtained from five different manufacturers. Thus, we present a new robust, reliable, and general method for measuring the antigenic content of SARS-CoV-2 protein subunit vaccines. In addition to currently marketed and emergency vaccines, it is suitable for vaccines in development containing antigens derived from pre-Omicron mutant strains.
Collapse
Affiliation(s)
- Lu Han
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
- College of Pharmacy, China Pharmaceutical University, Nanjing 210000, China
| | - Chaoqiang An
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
- Beijing Minhai Biotechnology Co., Ltd., Beijing 102629, China
| | - Dong Liu
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
- Changchun Institute of Biological Products Co., Ltd., Changchun 130062, China
| | - Zejun Wang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430070, China
| | - Lianlian Bian
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| | - Qian He
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| | - Jianyang Liu
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| | - Qian Wang
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| | - Mingchen Liu
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| | - Qunying Mao
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| | - Taijun Hang
- College of Pharmacy, China Pharmaceutical University, Nanjing 210000, China
| | - Aiping Wang
- College of Life Sciences, Zheng Zhou University, Zhengzhou 450001, China
| | - Fan Gao
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| | - Dejiang Tan
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| | - Zhenglun Liang
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China
| |
Collapse
|
14
|
Kosobucki P, Studziński W, Zuo S. The role of analytical chemistry in poultry science. PHYSICAL SCIENCES REVIEWS 2022. [DOI: 10.1515/psr-2021-0126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Abstract
Due to the intensification of food production methods, an increase in the importance of analytical chemistry can be observed. Analytical chemistry is on the one hand a scientific activity that brings new elements to the methodology of analytical chemistry, e.g. theoretical fundamentals of analytical methods, and on the other hand, this field of chemistry cannot exist without practical applications. Currently, it is used in all aspects of our life, including food production of particular importance.
Collapse
Affiliation(s)
- Przemysław Kosobucki
- Department of Food Analysis and Environmental Protection, Faculty of Chemical Technology and Engineering , Bydgoszcz University of Science and Technology , 3 Seminaryjna Street, 85-326 Bydgoszcz , Poland
| | - Waldemar Studziński
- Department of Food Analysis and Environmental Protection, Faculty of Chemical Technology and Engineering , Bydgoszcz University of Science and Technology , 3 Seminaryjna Street, 85-326 Bydgoszcz , Poland
| | - Sanling Zuo
- Department of Oncology , Faculty of Health Sciences , Collegium Medicum Nicolaus Copernicus University , Łukasiewicza 1 , Bydgoszcz , Poland
| |
Collapse
|
15
|
Park G, Kim MK, Go SH, Choi M, Jang YP. Analytical Quality by Design (AQbD) Approach to the Development of Analytical Procedures for Medicinal Plants. PLANTS (BASEL, SWITZERLAND) 2022; 11:2960. [PMID: 36365413 PMCID: PMC9653622 DOI: 10.3390/plants11212960] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 10/25/2022] [Accepted: 10/25/2022] [Indexed: 05/14/2023]
Abstract
Scientific regulatory systems with suitable analytical methods for monitoring quality, safety, and efficacy are essential in medicinal plant drug discovery. There have been only few attempts to adopt the analytical quality by design (AQbD) strategy in medicinal plants analysis over the last few years. AQbD is a holistic method and development approach that understands analytical procedure, from risk assessment to lifecycle management. The enhanced AQbD approach reduces the time and effort necessary to develop reliable analytical methods, leads to flexible change control through the method operable design region (MODR), and lowers the out-of-specification (OOS) results. However, it is difficult to follow all the AQbD workflow steps in the field of medicinal plants analysis, such as defining the analytical target profiles (ATPs), identifying critical analytical procedure parameters (CAPPs), among others, because the complexity of chemical and biological properties in medicinal plants acts as a barrier. In this review, various applications of AQbD to medicinal plant analytical procedures are discussed. Unlike the analysis of a single compound, medicinal plant analysis is characterized by analyzing multiple components contained in biological materials, so it will be summarized by focusing on the following points: Analytical methods showing correlations within analysis parameters for the specific medicinal plant analysis, plant raw material diversity, one or more analysis targets defined for multiple phytochemicals, key analysis attributes, and analysis control strategies. In addition, the opportunities available through the use of design-based quality management techniques and the challenges that coexist are also discussed.
Collapse
Affiliation(s)
- Geonha Park
- Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Korea
| | - Min Kyoung Kim
- Division of Pharmacognosy, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea
| | - Seung Hyeon Go
- Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Korea
| | - Minsik Choi
- Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Korea
| | - Young Pyo Jang
- Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Korea
- Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Korea
- Department of Integrated Drug Development and Natural Products, Graduate School, Kyung Hee University, Seoul 02447, Korea
| |
Collapse
|
16
|
Orlandini S, Hancu G, Szabó ZI, Modroiu A, Papp LA, Gotti R, Furlanetto S. New Trends in the Quality Control of Enantiomeric Drugs: Quality by Design-Compliant Development of Chiral Capillary Electrophoresis Methods. Molecules 2022; 27:7058. [PMID: 36296650 PMCID: PMC9607418 DOI: 10.3390/molecules27207058] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 10/14/2022] [Accepted: 10/17/2022] [Indexed: 11/16/2022] Open
Abstract
Capillary electrophoresis (CE) is a potent method for analyzing chiral substances and is commonly used in the enantioseparation and chiral purity control of pharmaceuticals from different matrices. The adoption of Quality by Design (QbD) concepts in analytical method development, optimization and validation is a widespread trend observed in various analytical approaches including chiral CE. The application of Analytical QbD (AQbD) leads to the development of analytical methods based on sound science combined with risk management, and to a well understood process clarifying the influence of method parameters on the analytical output. The Design of Experiments (DoE) method employing chemometric tools is an essential part of QbD-based method development, allowing for the simultaneous evaluation of experimental parameters as well as their interaction. In 2022 the International Council for Harmonization (ICH) released two draft guidelines (ICH Q14 and ICH Q2(R2)) that are intended to encourage more robust analytical procedures. The ICH Q14 guideline intends to harmonize the scientific approaches for analytical procedures' development, while the Q2(R2) document covers the validation principles for the use of analytical procedures including the recent applications that require multivariate statistical analyses. The aim of this review is to provide an overview of the new prospects for chiral CE method development applied for the enantiomeric purity control of pharmaceuticals using AQbD principles. The review also provides an overview of recent research (2012-2022) on the applicability of CE methods in chiral drug impurity profiling.
Collapse
Affiliation(s)
- Serena Orlandini
- Department of Chemistry “U. Schiff”, University of Florence, 50019 Florence, Italy
| | - Gabriel Hancu
- Department of Pharmaceutical and Therapeutic Chemistry, Faculty of Pharmacy, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Târgu Mureș, 540139 Târgu Mureș, Romania
| | - Zoltán-István Szabó
- Department of Pharmaceutical Industry and Management, Faculty of Pharmacy, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Târgu Mureș, 540139 Târgu Mureș, Romania
| | - Adriana Modroiu
- Department of Pharmaceutical and Therapeutic Chemistry, Faculty of Pharmacy, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Târgu Mureș, 540139 Târgu Mureș, Romania
| | - Lajos-Attila Papp
- Department of Pharmaceutical and Therapeutic Chemistry, Faculty of Pharmacy, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Târgu Mureș, 540139 Târgu Mureș, Romania
| | - Roberto Gotti
- Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy
| | - Sandra Furlanetto
- Department of Chemistry “U. Schiff”, University of Florence, 50019 Florence, Italy
| |
Collapse
|
17
|
Szoleczky R, Budai-Szűcs M, Csányi E, Berkó S, Tonka-Nagy P, Csóka I, Kovács A. Analytical Quality by Design (AQbD) Approach to the Development of In Vitro Release Test for Topical Hydrogel. Pharmaceutics 2022; 14:707. [PMID: 35456541 PMCID: PMC9026520 DOI: 10.3390/pharmaceutics14040707] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 03/22/2022] [Accepted: 03/23/2022] [Indexed: 11/16/2022] Open
Abstract
The aim of our study was to adapt the analytical quality by design (AQbD) approach to design an effective in vitro release test method using USP apparatus IV with a semi-solid adapter (SSA) for diclofenac sodium hydrogel. The analytical target profile (ATP) of the in vitro release test and ultra-high-performance liquid chromatography were defined; the critical method attributes (CMAs) (min. 70% of the drug should be released during the test, six time points should be obtained in the linear portion of the drug release profile, and the relative standard deviation of the released drug should not be over 10%) were selected. An initial risk assessment was carried out, in which the CMAs (ionic strength, the pH of the media, membrane type, the rate of flow, the volume of the SSA (sample amount), the individual flow rate of cells, drug concentration %, and the composition of the product) were identified. With the results, it was possible to determine the high-risk parameters of the in vitro drug release studies performed with the USP apparatus IV with SSA, which were the pH of the medium and the sample weight of the product. Focusing on these parameters, we developed a test protocol for our hydrogel system.
Collapse
Affiliation(s)
- Réka Szoleczky
- Egis Pharmaceuticals Plc., Laboratory of Finished Product Analytical Development 3, Bökényföldi Str. 116-120, 1165 Budapest, Hungary; (R.S.); (P.T.-N.)
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Str. 6, 6720 Szeged, Hungary; (M.B.-S.); (E.C.); (S.B.); (I.C.)
| | - Mária Budai-Szűcs
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Str. 6, 6720 Szeged, Hungary; (M.B.-S.); (E.C.); (S.B.); (I.C.)
| | - Erzsébet Csányi
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Str. 6, 6720 Szeged, Hungary; (M.B.-S.); (E.C.); (S.B.); (I.C.)
| | - Szilvia Berkó
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Str. 6, 6720 Szeged, Hungary; (M.B.-S.); (E.C.); (S.B.); (I.C.)
| | - Péter Tonka-Nagy
- Egis Pharmaceuticals Plc., Laboratory of Finished Product Analytical Development 3, Bökényföldi Str. 116-120, 1165 Budapest, Hungary; (R.S.); (P.T.-N.)
| | - Ildikó Csóka
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Str. 6, 6720 Szeged, Hungary; (M.B.-S.); (E.C.); (S.B.); (I.C.)
| | - Anita Kovács
- Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Str. 6, 6720 Szeged, Hungary; (M.B.-S.); (E.C.); (S.B.); (I.C.)
| |
Collapse
|
18
|
Affiliation(s)
- Andrew Teasdale
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Phil J. Borman
- Director & Senior Fellow, Product Development & Supply, Medicinal Science & Technology, Pharma R&D, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
| | - Alexander K. Mullen
- AstraZeneca Global Sustainability and Product Environmental Sustainability, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| |
Collapse
|
19
|
Analytical Quality-by-Design optimization of UHPLC method for the analysis of octreotide release from a peptide-based hydrogel in-vitro. J Pharm Biomed Anal 2022; 214:114699. [DOI: 10.1016/j.jpba.2022.114699] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Revised: 02/28/2022] [Accepted: 02/28/2022] [Indexed: 11/17/2022]
|
20
|
Verch T, Campa C, Chéry CC, Frenkel R, Graul T, Jaya N, Nakhle B, Springall J, Starkey J, Wypych J, Ranheim T. Analytical Quality by Design, Life Cycle Management, and Method Control. AAPS J 2022; 24:34. [DOI: 10.1208/s12248-022-00685-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2021] [Accepted: 01/19/2022] [Indexed: 11/30/2022] Open
Abstract
AbstractAnalytical methods are utilized throughout the biopharmaceutical and vaccines industries to conduct research and development, and to help control manufacturing inputs and outputs. These analytical methods should continuously provide quality data to support decisions while managing the remaining of risk and uncertainty. Analytical quality by design (AQbD) can provide a systematic framework to achieve a continuously validated, robust assay as well as life cycle management. AQbD is rooted in ICH guidelines Q8 and Q9 that were translated to the analytical space through several white papers as well as upcoming USP 1220 and ICH Q14. In this white paper, we expand on the previously published concepts of AQbD by providing additional context for implementation in relation to ICH Q14. Using illustrative examples, we describe the AQbD workflow, its relation to traditional approaches, and potential pathways for ongoing, real-time verification. We will also discuss challenges with respect to implementation and regulatory strategies.
Collapse
|